Testing CS2009 for advanced solid tumors

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors

This study is testing a new drug called CS2009 to see if it is safe and effective for people with advanced solid tumors.

Quick facts

• Phase: PHASE1; PHASE2
• Study type: Interventional
• Enrollment: 660 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: CStone Pharmaceuticals (industry)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 31 sites (Melbourne and 30 other locations)
• Trial ID: NCT06741644 on ClinicalTrials.gov

What this trial studies

This Phase I study evaluates the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 in participants with advanced solid tumors. It includes a dose escalation phase (Phase Ia) followed by a dose expansion phase (Phase Ib) to determine the optimal dosing and assess the drug's effects. The study is open-label and multi-center, allowing for a diverse participant pool to better understand the drug's impact across various tumor types.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with unresectable advanced solid tumors who have failed standard treatments or have no available options.

Not a fit: Patients with resectable tumors or those who have not yet undergone standard treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with advanced solid tumors who have exhausted standard therapies.

How similar studies have performed: Other studies involving tri-specific antibodies and similar immunotherapeutic approaches have shown promise, indicating potential for success in this novel application.

Eligibility criteria

Inclusion Criteria:

* Evidence of a personally signed and dated informed consent document.
* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
* Age ≥ 18 years on the day of signing informed consent.

Phase I:

* Pathologically or cytologically confirmed, unresectable advanced solid tumors, including but not limited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastric cancer (GC), ovarian cancer (OC), cervical cancer (CC), etc.
* Failure of established standard of care for advanced disease, or no available standard of care.

Phase II:

* Pathologically or cytologically confirmed unresectable advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), etc.
* Participants with at least one measurable lesion as defined per RECIST v1.1 solid tumor.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate organ function.
* Fertile male participants and female participants of childbearing potential must be willing to use an effective method of birth control from providing signed consent and for 180 days after the last investigational product administration.
* Female participants of childbearing potential must have a negative pregnancy test ≤ 7 days prior to the first dose of the investigational product.

Exclusion Criteria:

* History of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
* Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is either symptomatic, untreated, or requires therapy.
* Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage within 4 weeks prior to the first dose of investigational product.
* Receipt of systemic corticosteroid treatment or any other form of immune suppressing treatment within 7 days prior to the first dose of investigational product.
* Active or prior history of definite inflammatory bowel disease.
* History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or presence of active or suspected ILD/pneumonitis.
* Active infections requiring systemic therapy within 2 weeks prior to the first dose of investigational product.
* Positive for human immunodeficiency virus (HIV) or presence of acquired immune deficiency syndrome (AIDS).
* Active Hepatitis B or C infection.
* Active pulmonary tuberculosis (TB).
* Major surgery, chemotherapy, definitive radiotherapy, target therapy, immunotherapy, or other anti-cancer therapy within 21 days prior to the first dose of investigational product.
* Palliative radiotherapy within 14 days prior to the first dose of investigational product, or receipt of radioactive drug within 56 days prior to the first dose of investigational product.
* Administration of live vaccine within 28 days prior to the first dose of investigational product.
* History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
* Receipt of antitumor Chinese herbal preparations or Chinese patent medicine within 7 days prior to the first dose of investigational product.
* Receipt of any other investigational drugs within 21 days prior to the first dose in this trial.
* History of hypersensitivity or idiosyncrasy to the excipients of the study drug or any monoclonal antibody.
* Any toxic effects of prior therapy or surgical procedures unresolved to baseline severity or NCI-CTCAE Version 5.0 Grade ≤ 1.
* Active alcohol or drug abuse.
* Female participants who are pregnant or breastfeeding.
* Other acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or investigational product administration.

Where this trial is running

Melbourne and 30 other locations

• Alfred Hospital (Alfred Health) — Melbourne, Australia (RECRUITING)
• Austin Hospital (Austin Health) — Melbourne, Australia (RECRUITING)
• Monash Medical Centre (Monash Health) — Melbourne, Australia (RECRUITING)
• Peter Maccallum Cancer Centre Research — Melbourne, Australia (RECRUITING)
• Icon Cancer Centre South Brisbane — South Brisbane, Australia (RECRUITING)
• Blacktown Hospital — Sydney, Australia (RECRUITING)
• Macquarie University Hospital — Sydney, Australia (RECRUITING)
• Scientia Clinical Research Ltd — Sydney, Australia (RECRUITING)
• Beijing Cancer Hospital — Beijing, China (RECRUITING)
• Jilin Cancer Hospital — Changchun, China (RECRUITING)
• Hunan Cancer Hospital — Changsha, China (NOT_YET_RECRUITING)
• Sichuan Cancer Hospital — Chengdu, China (RECRUITING)
• West China Hospital of Sichuan University — Chengdu, China (RECRUITING)
• Fujian Cancer Hospital — Fuzhou, China (RECRUITING)
• Sun Yat-sen Memorial Hospital, Sun Yat-sen University — Guangzhou, China (RECRUITING)
• Sun Yat-Sen University Cancer Center — Guangzhou, China (NOT_YET_RECRUITING)
• The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, China (NOT_YET_RECRUITING)
• Zhejiang Cancer Hospital — Hangzhou, China (RECRUITING)
• Harbin Medical University Cancer Hospital — Harbin, China (RECRUITING)
• Anhui Provincial Hospital — Hefei, China (RECRUITING)
• Central Hospital Affiliated to Shandong First Medical University — Jinan, China (RECRUITING)
• Linyi Cancer Hospital — Linyi, China (RECRUITING)
• The First Affiliated Hospital of Nanchang University — Nanchang, China (RECRUITING)
• Nanjing Drum Tower Hospital — Nanjing, China (RECRUITING)
• Fudan University Shanghai Cancer Center — Shanghai, China (RECRUITING)
• Shanghai East Hospital — Shanghai, China (RECRUITING)
• Shanghai Pulmonary Hospital — Shanghai, China (RECRUITING)
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China (RECRUITING)
• Xuzhou Central Hospital — Xuzhou, China (RECRUITING)
• Henan Cancer Hospital — Zhengzhou, China (RECRUITING)
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, China (RECRUITING)

Study contacts

• Study coordinator: Jingru Wang

Conditions: Advanced Solid Tumors, PD-1, VEGFA, CTLA4, tri-specific antibody, advanced solid tumors, Phase I